TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Protocol for the Treatment of Adults Aged </= 60 Years With De Novo Acute Myeloblastic Leukaemia or Secondary AML or RAEB-T (AML 01/99 Trial)
Brief Summary: This randomized phase II/III trial investigates the antileukemic activity and toxicity of the FLAG-Ida regimen as a second induction course in patients with acute myeloid leukaemia and bad response to the first induction cycle and/or with a high risk karyotype and compares the antileukemic activity and toxicity of high dose cytarabine/daunorubicin vs. autologous peripheral blood stem cell transplantation as late consolidation therapy in standard risk patients.


Options:
A: Intervention Type: DRUG; Name: Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: early allogeneic PBSCT within induction therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous PBSCT; Assigned to Arm(s): N/A
B: Arm Label: Cytarabine low dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytarabine | Arm Label: Cytarabine intermediate dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytarabine | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): Cytarabine intermediate dose, Cytarabine low dose
C: Arm Label: Arm1 = Aracytine + Daunorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: chemotherapy (Aracytine + Daunorubicin) | Arm Label: Arm 3 = Aracytine And Idarubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: chemotherapy (Aracytine + Daunorubicin) | Arm Label: Arm 2 = Aracytine And Idarubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: chemotherapy (Aracytine + Daunorubicin) | Intervention Type: DRUG; Name: chemotherapy (Aracytine + Daunorubicin); Assigned to Arm(s): Arm1 = Aracytine + Daunorubicin | Intervention Type: DRUG; Name: chemotherapy (Aracytine + Daunorubicin); Assigned to Arm(s): Arm 2 = Aracytine And Idarubicin | Intervention Type: DRUG; Name: chemotherapy (Aracytine + Daunorubicin); Assigned to Arm(s): Arm 3 = Aracytine And Idarubicin
D: Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Idarubicin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Daunorubicine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Surgical Resection With or Without Axillary Lymph Node Excision in Treating Menopausal Women With Infiltrative Breast Cancer Smaller Than 10 mm
Brief Summary: This randomized phase III trial is studying surgery and axillary lymph node dissection to evaluate if systematic axillary node clearance can be avoided in locoregional treatment for operable breast cancer smaller than 10 mm among menopausal women older than 50


Options:
A: Intervention Type: PROCEDURE; Name: Conventional surgery; Assigned to Arm(s): N/A
B: Arm Label: Arm I: Conventional axillary dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: conventional surgery | Arm Label: Arm II: Sentinel node resection followed by node examination; Type: EXPERIMENTAL; Interventions: Procedure: Sentinel node resection followed by node examination | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I: Conventional axillary dissection | Intervention Type: PROCEDURE; Name: Sentinel node resection followed by node examination; Assigned to Arm(s): Arm II: Sentinel node resection followed by node examination
C: Arm Label: axillary lymph node dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: axillary lymph node dissection, Procedure: lymphoscintigraphy, Procedure: therapeutic conventional surgery | Arm Label: axillary radiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: lymphoscintigraphy, Procedure: therapeutic conventional surgery, Radiation: radiation therapy | Intervention Type: PROCEDURE; Name: axillary lymph node dissection; Assigned to Arm(s): axillary lymph node dissection | Intervention Type: PROCEDURE; Name: lymphoscintigraphy; Assigned to Arm(s): axillary lymph node dissection, axillary radiotherapy | Intervention Type: PROCEDURE; Name: therapeutic conventional surgery; Assigned to Arm(s): axillary lymph node dissection, axillary radiotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): axillary radiotherapy
D: Arm Label: Axillary Dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Axillary lymph node dissection | Arm Label: No Axillary Dissection; Type: EXPERIMENTAL; Interventions: Procedure: No axillary lymph node dissection | Intervention Type: PROCEDURE; Name: Axillary lymph node dissection; Assigned to Arm(s): Axillary Dissection | Intervention Type: PROCEDURE; Name: No axillary lymph node dissection; Assigned to Arm(s): No Axillary Dissection

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Refractory Partial Seizures (Protocol 333369-EPY-2003 [Double-blind] and Protocol 333369-EPY-2006 [Open-label Extension])
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of the novel compound RWJ-333369 in reducing the frequency of seizures in patients with epilepsy.


Options:
A: Intervention Type: DRUG; Name: RWJ-333369; Assigned to Arm(s): N/A
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: RWJ 333369 | Intervention Type: DRUG; Name: RWJ 333369; Assigned to Arm(s): 001
C: Intervention Type: DRUG; Name: RWJ-333369; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: RWJ-333369; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study of the Efficacy and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
Brief Summary: The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).


Options:
A: Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: dapoxetine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia
Brief Summary: The purpose of this study is to compare the effectiveness and safety over 1 year of treatment of intramuscular injections of paliperidone palmitate and long-acting risperidone in patients with schizophrenia.


Options:
A: Arm Label: RISPERDAL CONSTA; Type: ACTIVE_COMPARATOR; Interventions: Drug: RISPERDAL CONSTA | Arm Label: R092670; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone palmitate | Intervention Type: DRUG; Name: RISPERDAL CONSTA; Assigned to Arm(s): RISPERDAL CONSTA | Intervention Type: DRUG; Name: Paliperidone palmitate; Assigned to Arm(s): R092670
B: Intervention Type: DRUG; Name: atypical antipsychotics:oral vs. long-acting route; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Family Psychoeducation; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): N/A
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: BL - 1020 | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: BL - 1020 | Arm Label: III; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: BL - 1020; Assigned to Arm(s): I | Intervention Type: DRUG; Name: BL - 1020; Assigned to Arm(s): II | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): III | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): IV

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia
Brief Summary: The purpose of this study is to compare the effectiveness and safety over 1 year of treatment of intramuscular injections of paliperidone palmitate and long-acting risperidone in patients with schizophrenia.


Options:
A: Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: perphenazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ziprasidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: clozapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluphenazine decanoate; Assigned to Arm(s): N/A
C: Arm Label: LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): LY2140023 | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Iloperidone; Type: EXPERIMENTAL; Interventions: Drug: Iloperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Iloperidone; Assigned to Arm(s): Iloperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind Trial Comparing the Efficacy, Tolerability and Safety of Monotherapy Topiramate Versus Phenytoin in Subjects With Seizures Indicative of New Onset Epilepsy
Brief Summary: The purpose of this study is to compare the effectiveness and safety of two treatment regimens, topiramate as compared to phenytoin, in preventing seizures in patients with new-onset epilepsy who require rapid initiation of antiepileptic drug therapy. Reasons for requiring rapid initiation of treatment, rather than slowly increasing an antiepileptic drug to an effective dose, may include severe or frequent seizures, or high risk to the patient of recurrent seizures.


Options:
A: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Carabamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carabamazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carabamazepine; Assigned to Arm(s): Carabamazepine
B: Intervention Type: DRUG; Name: phenobarbitone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carbamazepine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: topiramate, phenytoin; Assigned to Arm(s): N/A
D: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Older Antepileptic Drugs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine Controlled Release (CBZ-CR), Drug: Valproate Extended Release | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine Controlled Release (CBZ-CR); Assigned to Arm(s): Older Antepileptic Drugs | Intervention Type: DRUG; Name: Valproate Extended Release; Assigned to Arm(s): Older Antepileptic Drugs

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind Trial Comparing the Efficacy, Tolerability and Safety of Monotherapy Topiramate Versus Phenytoin in Subjects With Seizures Indicative of New Onset Epilepsy
Brief Summary: The purpose of this study is to compare the effectiveness and safety of two treatment regimens, topiramate as compared to phenytoin, in preventing seizures in patients with new-onset epilepsy who require rapid initiation of antiepileptic drug therapy. Reasons for requiring rapid initiation of treatment, rather than slowly increasing an antiepileptic drug to an effective dose, may include severe or frequent seizures, or high risk to the patient of recurrent seizures.


Options:
A: Arm Label: lamotrigine 300; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 300 mg/day | Arm Label: lamotrigine 250; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 250 mg/day | Intervention Type: DRUG; Name: lamotrigine, 300 mg/day; Assigned to Arm(s): lamotrigine 300 | Intervention Type: DRUG; Name: lamotrigine, 250 mg/day; Assigned to Arm(s): lamotrigine 250
B: Intervention Type: DRUG; Name: topiramate, phenytoin; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): 1
D: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Older Antepileptic Drugs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine Controlled Release (CBZ-CR), Drug: Valproate Extended Release | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine Controlled Release (CBZ-CR); Assigned to Arm(s): Older Antepileptic Drugs | Intervention Type: DRUG; Name: Valproate Extended Release; Assigned to Arm(s): Older Antepileptic Drugs

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind Trial Comparing the Efficacy, Tolerability and Safety of Monotherapy Topiramate Versus Phenytoin in Subjects With Seizures Indicative of New Onset Epilepsy
Brief Summary: The purpose of this study is to compare the effectiveness and safety of two treatment regimens, topiramate as compared to phenytoin, in preventing seizures in patients with new-onset epilepsy who require rapid initiation of antiepileptic drug therapy. Reasons for requiring rapid initiation of treatment, rather than slowly increasing an antiepileptic drug to an effective dose, may include severe or frequent seizures, or high risk to the patient of recurrent seizures.


Options:
A: Intervention Type: DRUG; Name: topiramate, phenytoin; Assigned to Arm(s): N/A
B: Arm Label: lamotrigine 300; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 300 mg/day | Arm Label: lamotrigine 250; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 250 mg/day | Intervention Type: DRUG; Name: lamotrigine, 300 mg/day; Assigned to Arm(s): lamotrigine 300 | Intervention Type: DRUG; Name: lamotrigine, 250 mg/day; Assigned to Arm(s): lamotrigine 250
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): 1
D: Arm Label: Carbamazepine controlled release; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eslicarbazepine acetate (BIA 2-093) | Arm Label: Eslicarbazepine acetate; Type: EXPERIMENTAL; Interventions: Drug: Eslicarbazepine acetate (BIA 2-093) | Intervention Type: DRUG; Name: Eslicarbazepine acetate (BIA 2-093); Assigned to Arm(s): Carbamazepine controlled release, Eslicarbazepine acetate

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Alcohol Dependence
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of topiramate compared to placebo in patients with alcohol dependence.


Options:
A: Intervention Type: DRUG; Name: topiramate; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: naltrexone (Revia); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: acamprosate (Campral); Assigned to Arm(s): N/A
C: Arm Label: Levetiracetam; Type: ACTIVE_COMPARATOR; Interventions: Drug: levetiracetam (Keppra) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: levetiracetam (Keppra); Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam (Keppra), Drug: Placebo | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam (Keppra), Drug: Placebo | Intervention Type: DRUG; Name: Levetiracetam (Keppra); Assigned to Arm(s): Group A, Group B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group A, Group B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Double-Blind Study Of Ceftobiprole Versus Linezolid Plus Ceftazidime In The Treatment Of Nosocomial Pneumonia
Brief Summary: The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug \[form\] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with nosocomial pneumonia.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002
B: Arm Label: Severe Pneumonia - Hospital Management; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Severe Pneumonia - Home Management; Type: EXPERIMENTAL; Interventions: Other: Severe Pneumonia - Home Management | Intervention Type: OTHER; Name: Severe Pneumonia - Home Management; Assigned to Arm(s): Severe Pneumonia - Home Management
C: Arm Label: Amoxicillin 45mg/kg 12 hourly; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin | Arm Label: Benzyl Penicillin 50,000IU/kg 6 hourly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benzyl penicillin | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): Amoxicillin 45mg/kg 12 hourly | Intervention Type: DRUG; Name: Benzyl penicillin; Assigned to Arm(s): Benzyl Penicillin 50,000IU/kg 6 hourly
D: Arm Label: Ceftobiprole medocaril; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole medocaril | Arm Label: IV standard-of-care cephalosporin; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV standard-of-care cephalosporin | Intervention Type: DRUG; Name: ceftobiprole medocaril; Assigned to Arm(s): Ceftobiprole medocaril | Intervention Type: DRUG; Name: IV standard-of-care cephalosporin; Assigned to Arm(s): IV standard-of-care cephalosporin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Double-Blind Study Of Ceftobiprole Versus Linezolid Plus Ceftazidime In The Treatment Of Nosocomial Pneumonia
Brief Summary: The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug \[form\] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with nosocomial pneumonia.


Options:
A: Arm Label: Doripenem; Type: EXPERIMENTAL; Interventions: Drug: Doripenem, Drug: Placebo | Arm Label: Imipenem-Cilastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipenem-Cilastatin, Drug: Placebo | Intervention Type: DRUG; Name: Doripenem; Assigned to Arm(s): Doripenem | Intervention Type: DRUG; Name: Imipenem-Cilastatin; Assigned to Arm(s): Imipenem-Cilastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Doripenem, Imipenem-Cilastatin
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: tigecycline | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: tigecycline | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: imipenem/cilastatin | Intervention Type: DRUG; Name: tigecycline; Assigned to Arm(s): A | Intervention Type: DRUG; Name: tigecycline; Assigned to Arm(s): B | Intervention Type: DRUG; Name: imipenem/cilastatin; Assigned to Arm(s): C
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open-Label, Phase 3 Study to Compare the Safety and Effectiveness of Doripenem Versus a Comparator Antibiotic in Hospital-Acquired Pneumonia
Brief Summary: The purpose of this study is to compare the safety and effectiveness of doripenem in patients with hospital-acquired pneumonia (HAP).


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002
B: Intervention Type: DRUG; Name: doripenem; Assigned to Arm(s): N/A
C: Arm Label: Doripenem; Type: EXPERIMENTAL; Interventions: Drug: Doripenem, Drug: Placebo | Arm Label: Imipenem-Cilastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipenem-Cilastatin, Drug: Placebo | Intervention Type: DRUG; Name: Doripenem; Assigned to Arm(s): Doripenem | Intervention Type: DRUG; Name: Imipenem-Cilastatin; Assigned to Arm(s): Imipenem-Cilastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Doripenem, Imipenem-Cilastatin
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-Controlled, Double-blind, Randomized, Parallel Study of the Efficacy and Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation
Brief Summary: The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).


Options:
A: Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: dapoxetine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): N/A

Answer: A